Activity of partially inhibited serine palmitoyltransferase is sufficient for normal sphingolipid metabolism and viability of HSN1 patient cells

被引:30
作者
Dedov, VN
Dedova, IV
Merrill, AH
Nicholson, GA
机构
[1] Concord Repatriat Gen Hosp, ANZAC Res Inst, Neurobiol Lab, Concord, NSW 2139, Australia
[2] Georgia Inst Technol, Sch Biol, Atlanta, GA 30332 USA
来源
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE | 2004年 / 1688卷 / 02期
关键词
hereditary sensory neuropathy; serine palmitoyltransferase; transformed lymphocyte; sphingolipid; cell proliferation; cell death;
D O I
10.1016/j.bbadis.2003.12.005
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Hereditary sensory neuropathy type 1 (HSN1) is a common degenerative disorder of peripheral sensory neurons. HSN1 is caused by mutations in the gene, encoding the long chain base 1 of serine palmitoyltransferase (SPT) [Nat. Genet. 27 (2001) 309]. Here, we show a 44% reduction of SPT activity in transformed lymphocytes from HSN1 patients with mutation T399G in the SPTLC1 gene. However, the decrease in SPT activity had no effect on de novo sphingolipid biosynthesis, cellular sphingolipid content, cell proliferation and death (apoptosis and necrosis). The removal of extracellular sphingolipids did not affect viability of HSN1 cells. We also found no significant difference in whole blood counts, viability, and permeability to Triton X-100 of primary lymphocytes from HSN1 patients. These results suggest that, despite the inhibition of mutant allele, the activity of nonmutant allele of STP may be sufficient for adequate sphingolipid biosynthesis and cell viability. Therefore, the neurodegeneration in HSN1 is likely to be caused by subtler and rather long-term effect(s) of these mutations such as loss of a cell-type selective facet of sphingolipid metabolism and/or function, or perhaps accumulation of toxic species, including abnormal protein(s) as in other neurodegenerations. (C) 2004 Elsevier B.V. All rights reserved.
引用
收藏
页码:168 / 175
页数:8
相关论文
共 34 条
  • [1] Characterization of serine palmitoyltransferase in normal human tissues
    Batheja, AD
    Uhlinger, DJ
    Carton, JM
    Ho, G
    D'Andrea, MR
    [J]. JOURNAL OF HISTOCHEMISTRY & CYTOCHEMISTRY, 2003, 51 (05) : 687 - 696
  • [2] SPTLC1 is mutated in hereditary sensory neuropathy, type 1
    Bejaoui, K
    Wu, CY
    Sheffler, MD
    Haan, G
    Ashby, P
    Wu, LC
    de Jong, P
    Brown, RH
    [J]. NATURE GENETICS, 2001, 27 (03) : 261 - 262
  • [3] Hereditary sensory neuropathy type 1 mutations confer dominant negative effects on serine palmitoyltransferase, critical for sphingolipid synthesis
    Bejaoui, K
    Uchida, Y
    Yasuda, S
    Ho, M
    Nishijima, M
    Brown, RH
    Holleran, WM
    Hanada, K
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 2002, 110 (09) : 1301 - 1308
  • [4] A YAC-based transcript map of human chromosome 9q22.1-q22.3 encompassing the loci for hereditary sensory neuropathy type I and multiple self-healing squamous epithelioma
    Blair, IP
    Hulme, D
    Dawkins, JL
    Nicholson, GA
    [J]. GENOMICS, 1998, 51 (02) : 277 - 281
  • [5] Fine mapping of the hereditary sensory neuropathy type I locus on chromosome 9q22.1->q22.3: exclusion of GAS1 and XPA
    Blair, IP
    Dawkins, JL
    Nicholson, GA
    [J]. CYTOGENETICS AND CELL GENETICS, 1997, 78 (02): : 140 - 144
  • [6] The identification of myriocin-binding proteins
    Chen, JK
    Lane, WS
    Schreiber, SL
    [J]. CHEMISTRY & BIOLOGY, 1999, 6 (04): : 221 - 235
  • [7] Exclusion of serine palmitoyltransferase long chain base subunit 2 (SPTLC2) as a common cause for hereditary sensory neuropathy
    Dawkins, JL
    Brahmbhatt, S
    Auer-Grumbach, M
    Wagner, K
    Hartung, HP
    Verhoeven, K
    Timmerman, V
    De Jonghe, P
    Kennerson, M
    LeGuern, E
    Nicholson, GA
    [J]. NEUROMUSCULAR DISORDERS, 2002, 12 (7-8) : 656 - 658
  • [8] Mutations in SPTLC1, encoding serine palmitoyltransferase, long chain base subunit-1, cause hereditary sensory neuropathy type I
    Dawkins, JL
    Hulme, DJ
    Brahmbhatt, SB
    Auer-Grumbach, M
    Nicholson, GA
    [J]. NATURE GENETICS, 2001, 27 (03) : 309 - 312
  • [9] Inhibition of topoisomerase II overrides the G2/M check points of the cell cycle in EBV-lymphocytes
    Dedov, VN
    Dedova, IV
    Nicholson, GA
    [J]. APOPTOSIS, 2003, 8 (04) : 399 - 406
  • [10] DYCK PJ, 1993, PERIPHERAL NEUROPATH, P1065